Filter
123
Text search:
delamanid
Featured
23
33
Language
Document type
77
18
12
7
3
2
2
1
1
Countries / Regions
14
11
4
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
31
18
3
1
1
Toolboxes
106
4
3
2
2
1
1
1
1
1
1
1
Information für Ärzte.
Int. J. Mol. Sci. 2017, 18, 341, 1 - 10
The use of Delamanid and Bedaquiline for Children with Drug-Resistant Tuberculosis.
For the first time in almost 50 years there are two new drugs for the treatment of drug-resistant TB (DR-TB): bedaquiline and delamanid. There has also been increased attention given to the safety and efficacy of “re-purposed” drugs that have be
...
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of bedaquiline and
...
Accessed November 2017
Report of a mission 20–24 April 2015
DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended
Issue Brief 8th edition.
Framework for implementation.
The END TB Strategy.
Report: A survey conducted among the 27 high MDR-TB burden countries.
March – July 2015
Stop TB Partnership in collaboration with Medecins Sans Frontieres (MSF).
Accessed November 2017.
TB policies in 29 Countries
A survey of prevention, testing and treatment policies and practices
Lancet Respir Med 2017; 5: 291–360Vol, 5 April 2017
Patients and TB: Improving treatment outcomes through a patient centred approach and access to new treatments
5th TB Symposium – Eastern Europe and Central Asia Ministry of Labour, Health and Social Affairs of Georgia and Médecins Sans Frontières
22- 23 March , 2016 , TBILISI , GEORGIA
